Some clinical trials have evaluated the mTOR inhibitor everolimus and the combination of sorafenib and the mTOR inhibitor temsirolimus in the treatment of RAI-R thyroid cancer. The gene discussed is MTOR; the disease is thyroid gland carcinoma.